Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bayer announces collaboration for pneumonia treatment

Bayer announces collaboration for pneumonia treatment

8th August 2007

Bayer HealthCare has announced that it is to collaborate with Nektar Therapeutics on the development of a novel treatment for Gram-negative pneumonias.

The innovative treatment method will make use of proprietary pulmonary technology from Nektar for the delivery of a specially formulated aminoglycoside antibiotic – amikacin (NKTR-061) – to facilitate its deep inhalation into the lungs.

Under the terms of the agreement, Bayer will pay Nektar an initial licensing fee of $50 million (24.5 million pounds), with further milestone payments of an additional $125 million on the attainment of specific development and marketing landmarks.

Bayer will be responsible for global clinical development, regulatory filing, production and commercialisation of the finished product, with the firms co-promoting the product in the US.

Dr Ulrich Kostlin, board member responsible for primary care at Bayer Schering Pharma, said: “This development agreement reinforces our commitment to fight infectious and respiratory diseases and is a natural fit with Bayer HealthCare’s strategy of developing and marketing specialty pharmaceutical products.”

President and chief executive officer of Nektar, Howard W Robin echoed this comment, stating that the firms are building upon their joint development experience in the field of pulmonary therapies.

Following the acquisition of Schering AG, Bayer HealthCare Pharmaceuticals was launched in the US – incorporating Berlex into the firm – in April 2007.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.